Relationship between SNPs of ERCC1 in peripheral blood of NSCLC and effects of cisplatin-based chemotherapy

Chinese Journal of Cancer Prevention and Treatment

Volumn 17, Issue 3, 2010, Pages 169-172

  Li, Xiao Hui ^a   Jiang, Wei Feng ^a   Zhang, He Long ^a   Zhang, Ju ^b  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Blood; Carcinoma, non small cell lung; Cisplatin; Polymorphism, single nucleotide

Indexed keywords

CISPLATIN; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; GEMCITABINE;

ADULT; BLOOD; CODON; FEMALE; FLUORESCENCE POLARIZATION IMMUNOASSAY; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; SHORT SURVEY; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; TREATMENT RESPONSE;

EID: 77953442041     PISSN: 16735269     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (14)

1. Schiller J H, Harrington D, Belani C P, et al. Comparison of four chemotherapy regimens for advanced non-small cell lung cancer[J]. N Engl J Med, 2002, 346:92-98. (Pubitemid 34438899)
2. Niedernhofer L J, Odijk H, Budzowska M, et al. The structure specific endonuclease Ercc1-Xpf is required to resolve DNA interstrand cross-link -induced double-strand breaks[J], Mol Cell Biol, 2004, 24(13):5776-5787.
3. Su D, Ma S, Liu P, et al. Genetic polymorphisms and treatment response in advanced non-small cell lung cancer[J]. Lung Cancer, 2007, 56(2):281-288. (Pubitemid 46590484)
4. Tibaldi C, Giovannetti E, Vasile E, et al. Correlation of CDA, ERCC1 and XPD polymorphisms with response and survival in Gemcitabine/Cisplatin-treated advanced non-small cell lung cancer patients[J]. Clin Cancer Res, 2008, 14(6),1797-1803.
5. Sasaki T. New guidelines to evaluate the response to treatment "RECIST" [J]. Gan To Kagaku Ryoho, 2000, 27(14):2179-2184.
6. Rosell R, Felip E, Paz-Ares L. How could pharmacogenomics help improve patient survival? [J]. Lung Cancer, 2007, 57(Suppl 2):S35-S41.
7. Lenz H J. The use and development of germline polymorphisms in clinical oncology[J]. J Clin Oncol, 2004, 22(13):2519-2521. (Pubitemid 41103738)
8. Park D J, Zhang S J, Tsao-Wei W, et al. ERCC1 polymorphism is associated with differential ERCC1 geneexpression[C]. American Association for Cancer Research 93th Annual Meeting Proceedings, 2002, 43:1519.
9. Viguier J, Boige V, Miquel C, et al. ERCC1 codon 118 polymorphism is a predictive factor for the tumor response to oxaliplatin/ 5-fluorouracil combination chemotherapy in patients with advanced colorectal cancer [J]. Clin Cancer Res, 2005, 11(17):6212-6217. (Pubitemid 41262950)
10. Kang S, Ju W, Kim J W, et al. Association between excision repair cross-complementation group 1 polymorphism and clinical outcome of platinum-based chemotherapy in patients with epithelial ovarian cancer[J]. Exp Mol Med, 2006, 38(3):320-324. (Pubitemid 44033245)